Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Editor

Personal info

View

About

Terms

Javascript disabled

Please enable Javascript support in your browser to use this application.

Instructions on how to enable JavaScript on different browsers can be found here: http://www.google.com/support/bin/answer.py?answer=23852.

[edit this page]

Chemical Compound Review:

Poly ICLC [5-(4-amino-2-oxo-pyrimidin- 1-yl)-3,4...

Synonyms: NSC-301463, AC1L8SGX, NSC301463, 34354-71-7, Poly-IC-poly-L-lysine

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of NSC301463

Poly-ICLC can be used to enhance IL-2-induced NK lytic activity without increases in the dose and, therefore, the toxicity of IL-2 treatment [1].
Poly ICLC in the treatment of postinfectious demyelinating encephalomyelitis [2].
(iii) Poly ICLC (4S) induced high titers of serum interferon and fever, but no hypotension [3].
PURPOSE: Phase II studies were conducted to evaluate the safety and efficacy of the interferon inducer Poly ICLC at low doses in advanced renal cancer and relapsed or refractory lymphoma [4].
Poly ICLC pretreatment also protects mice against a respiratory challenge of western equine encephalitis (WEE) virus, at a level comparable to inactivated WEE vaccine [5].

High impact information on NSC301463

Poly ICLC significantly suppressed serum-induced [3H]thymidine incorporation by quiescent fibroblasts in all cell lines [6].
Poly ICLC is a synthetic double-stranded RNA (dsRNA), and an effective interferon-inducer and natural killer cell activator [5].
Poly ICLC treatment of infected mice caused no change in blood parasitaemia but resulted in a significant increase in GSH, glutathione reductase, SOD and catalase with respect to infected mice [7].
To investigate the cellular immune effects of the interferon inducer, Poly ICLC, in humans, peripheral blood mononuclear cells from patients with multiple sclerosis receiving Poly ICLC as part of a preliminary clinical trial were studied [8].
The results indicate Poly-ICLC to be a T cell stimulator [9].

Biological context of NSC301463

The cellular mechanism of the increased radiosensitivity caused by Poly (ICLC) was reflected in the reduction of the width of the shoulder on the cell survival curve, which was dependent on the dose of the drug [10].

Anatomical context of NSC301463

Poly ICLC did not induce DNA synthesis in subconfluent, quiescent or in confluent, quiescent fibroblasts under serum-free conditions [6].

Associations of NSC301463 with other chemical compounds

Of the five BRMs tested, MVE-2, Poly ICLC, OK-432, and alpha beta IFN were capable of stimulating both natural killer (NK) cell and macrophage (M phi) tumoricidal activity, whereas BM 41-332 augmented only NK cells [11].

Gene context of NSC301463

Poly ICLC is an interferon (IFN) inducer and antiviral, antitumor, radioprotective, and immunoregulatory agent [12].

Analytical, diagnostic and therapeutic context of NSC301463

Poly ICLC was encapsulated in cationic liposomes prepared by the freeze drying method [13].
The same doses of Poly (ICLC) potentiated the epilation effect of radiation [10].

References

Polyinosinic-polycytidylic acid complexed with poly-L-lysine and carboxymethylcellulose in combination with interleukin 2 in patients with cancer: clinical and immunological effects. Ewel, C.H., Urba, W.J., Kopp, W.C., Smith, J.W., Steis, R.G., Rossio, J.L., Longo, D.L., Jones, M.J., Alvord, W.G., Pinsky, C.M. Cancer Res. (1992) [Pubmed]
Poly ICLC in the treatment of postinfectious demyelinating encephalomyelitis. Salazar, A.M., Engel, W.K., Levy, H.B. Arch. Neurol. (1981) [Pubmed]
Modified polyriboinosinic-polyribocytidylic acid complex: induction of serum interferon, fever, and hypotension in rabbits. Gatmaitan, B.G., Legaspi, R.C., Levy, H.B., Lerner, A.M. Antimicrob. Agents Chemother. (1980) [Pubmed]
Toxicity and response evaluation of the interferon inducer poly ICLC administered at low dose in advanced renal carcinoma and relapsed or refractory lymphoma: a report of two clinical trials of the Eastern Cooperative Oncology Group. Giantonio, B.J., Hochster, H., Blum, R., Wiernik, P.H., Hudes, G.R., Kirkwood, J., Trump, D., Oken, M.M. Investigational new drugs. (2001) [Pubmed]
Prophylaxis of acute respiratory virus infections using nucleic acid-based drugs. Wong, J.P., Nagata, L.P., Christopher, M.E., Salazar, A.M., Dale, R.M. Vaccine (2005) [Pubmed]
Double-stranded RNA regulation of DNA synthesis in fibroblasts. Perricone, M.A., Giri, S.N., Hyde, D.M. Exp. Cell Res. (1992) [Pubmed]
Studies on hepatic oxidative stress and antioxidant defence system during chloroquine/poly ICLC treatment of Plasmodium yoelii nigeriensis infected mice. Siddiqi, N.J., Puri, S.K., Dutta, G.P., Maheshwari, R.K., Pandey, V.C. Mol. Cell. Biochem. (1999) [Pubmed]
Changes in leukocyte recirculation, NK cell activity, and HLA-DR expression in peripheral blood mononuclear cells of MS patients treated with Poly ICLC. Bever, C.T., Jacobson, S., Mingioli, E.S., McFarland, H.F., McFarlin, D.E., Levy, H.B. Int. J. Immunopharmacol. (1991) [Pubmed]
Immune response modifying activity in mice of polyinosinic: polycytidylic acid stabilized with poly-L-lysine, in carboxymethylcellulose [poly-ICLC]. Chirigos, M.A., Papademetriou, V., Bartocci, A., Read, E., Levy, H.B. Int. J. Immunopharmacol. (1981) [Pubmed]
Tumor response to interferon inducer and radiation effect of serum interferon levels. Lvovsky, E.A., D'Souza, J., Eng, D., D'Souza, D., Lvovsky, B., Hetland, R., Craver, W.L., Sobel, S.H. J. Biol. Regul. Homeost. Agents (1988) [Pubmed]
Biological response modifiers: regulators of the cellular immune system and adjuvants in antitumor therapy. Chirigos, M.A., Schlick, E., Saito, T., Gruys, E. Methods and findings in experimental and clinical pharmacology. (1986) [Pubmed]
Poly ICLC induces anti-IC antibodies in mice and rabbits. Granados, E.N., Alm, T., O'Malley, J.A., McGarry, M., Bello, J. J. Interferon Res. (1984) [Pubmed]
Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. Wong, J.P., Yang, H., Nagata, L., Kende, M., Levy, H., Schnell, G., Blasetti, K. Vaccine (1999) [Pubmed]

Contributions to this collaborative article are from individual authors of WikiGenes or mined by the WikiGenes Data Mining Engine from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenes Open Access Licence Privacy Policy Terms of Use apsburg

The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.